CD276 and nonpapillary renal cell carcinoma: Therefore, we can boldly speculate that evenif patients with ccRCC have never received sunitinib chemotherapy before and areunaware of their sensitivity to sunitinib, they can still try adjunctive treatmentmeasures that downregulate CD276 expression to effectively enhance the efficacy ofsunitinib.